Antibody Therapy

Alexion Completes Phase I Dermatomyositis Pilot Safety Study

Published in Vaccine Weekly, January 16th, 2002

Alexion Pharmaceuticals, Inc., announced that it has completed a two-month Phase I pilot safety trial in dermatomyositis patients with its humanized monoclonal antibody C5 complement inhibitor, 5G1.1.

In this 13 patient pilot trial, 5G1.1 appeared to be well tolerated and to be associated with an improvement in skin rash. Dermatomyositis is a connective tissue disease associated with both skin and muscle inflammation resulting in severe skin rash and muscle weakness. Alexion has previously received orphan drug status for 5G1.1 in this disease setting.

"This exploratory pilot trial fulfilled our expectations of identifying a positive signal of 5G1.1...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-01-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry